Field Notes.

September 16, 2026

The FDA Approved This Valve for Symptom-Free Patients. Medicare Started Paying Sixteen Months Later.

Edwards had FDA approval to treat severe aortic stenosis in patients with no symptoms on May 1, 2025. Medicare finalized coverage for those same patients on September 11, 2026, and attached an ongoing evidence requirement to it. The approval that lets you sell and the decision that lets anyone buy run on separate clocks.

September 15, 2026

When No Law Fits Your Product, Regulators Reach for the Nearest One

A 1986 White House policy decision put engineered microbes under the Toxic Substances Control Act, a law written in 1976 for industrial chemicals. Researchers filed more than 240 applications between 1987 and 2018 and only a few were ever approved. Every hard-tech category gets its law assigned the same way, early and quietly.

September 14, 2026

J&J Bought Into a $37 Billion Orthopedics Market. It's Leaving a $50 Billion One.

In 2011 J&J paid $21.3 billion for Synthes, citing a large and growing $37 billion orthopedics market. That market now sits above $50 billion, and Apollo is in talks to buy the combined DePuy Synthes for close to $20 billion. A market can grow for fifteen years and hand almost none of that growth to the business inside it.

September 13, 2026

GM Is Building Battery Cells It Will Never Sell So It Can Judge the Ones It Buys

GM is finishing a battery plant in Warren, Michigan whose thousands of cells are all for development work, part of $900 million in research and prototype facilities. The output of a pilot line is not cells. It is a process definition and the standing to read what a supplier tells you.

September 12, 2026

Teradyne Is Suing Over Three Universal Robots Patents. All Three Expire in March.

Teradyne Robotics is suing JAKA at the Unified Patent Court over three Universal Robots patents. All three were filed on March 2, 2007 and expire on March 2, 2027. What carries Universal Robots past that date is the 100,000 arms already sold and the decade of integrator and software work around them, which is the part no examiner can put a term limit on.

September 11, 2026

Axogen Paid $200 Million to Widen the Pool of Surgeons Who Can Repair a Nerve

Axogen is paying $200 million in cash for BioCircuit Technologies and its sutureless nerve repair device, NerveTape. The device's value is that the repair no longer needs a surgeon trained in microsuture, which changes how many surgeons can do the operation at all. A closing condition says what Axogen declined to buy.

September 10, 2026

Nine Sites, $1.8 Million: How to Read a Hardware Company's Traction

Agility Robotics' S-4 puts numbers behind a word founders use loosely. More than 65,000 Digit operating hours across nine customer sites, and $1.8 million in 2025 net sales. Almost all of the commercial case for the $2.5 billion SPAC sits inside one unnamed customer's multi-year order, which is a shape worth learning to spot on your own numbers.